Insulin-like growth factor I increase glomerular filtration rate and renal plasma flow in man.
Recombinant IGF-I was infused seal at a dose of 20 micrograms-kg 1-h 1 to 2 healthy subjects during a total of 79 h. Serum levels of IGF-I rose from 93 and 177 to 502 and 616 micrograms/l, respectively. Fasting blood glucose remained normal. During the infusion glomerular filtration rate increased by 31%, in subject No. 1 and by 32% in subject No.2. Concomitantly, renal plasma flow increased by 26% and 22%, respectively. Proximal and distal tubular reabsorption of fluid and sodium as determined by lithium clearance was elevated to a similar extent. When determined again one week after the end of the IGF-I infusion, all parameters of renal function had returned to baseline. Sodium excretion, body weight and blood pressure did not change. We conclude that IGF-I infused at pharmacological doses has marked effects on kidney function. Future studies will necessary to define the clinical potential of recombinant IGF-I in the treatment of diseases characterized by impaired renal perfusion and filtration.
Guler
H P
HP
University Hospital, Metabolic Unit, Zürich, Switzerland.
Eckardt
K U
KU
Zapf
J
J
Bauer
C
C
Froesch
E R
ER
D000328:Adult; D005919:Glomerular Filtration Rate / Q000187:drug effects*; D006801:Humans; D007260:Infusion Pumps; D007334:Insulin-Like Growth Factor I / Q000008:administration & dosage*; D007684:Kidney Tubules / Q000378:metabolism; D008094:Lithium / Q000493:pharmacokinetics*; D018020:Lithium Compounds; D008297:Male; D012079:Renal Circulation / Q000187:drug effects*; D013002:Somatomedins / Q000008:administration & dosage*; D013431:Sulfates / Q000493:pharmacokinetics*
D018020:Lithium Compounds; D013002:Somatomedins; D013431:Sulfates; D007334:Insulin-Like Growth Factor I; C054097:lithium sulfate; D008094:Lithium